Divi's Laboratories gets broker support after strong Q2 results
In short
Divi’s Laboratories got a boost after strong Q2 results. JPMorgan upgraded the stock, Goldman lifted earnings estimates, and Motilal said the company is well placed for custom synthesis work.
What the reporting says
Divi’s Laboratories drew broker support after strong Q2 results, with the market brief saying JPMorgan upgraded the stock and Goldman raised earnings estimates. Motilal said the company is well positioned for custom synthesis business because of its capabilities in peptides, contrast media and generics, along with large-scale manufacturing and supply chain management. The comments point to stronger expectations for the drugmaker’s business mix.
Why it matters
Divi’s Laboratories attracted bullish broker comments after strong Q2 results. The market summary says JPMorgan upgraded the stock and Goldman raised earnings estimates, while Motilal highlighted the company’s strengths in peptides, contrast media and generics, plus large-scale manufacturing and supply chain execution. Those factors support expectations that Divi’s can secure more custom synthesis business.